CA2409950A1 - Compositions pharmaceutiques comprenant du desglymidodrine en tant que substance medicamenteuse active - Google Patents

Compositions pharmaceutiques comprenant du desglymidodrine en tant que substance medicamenteuse active Download PDF

Info

Publication number
CA2409950A1
CA2409950A1 CA002409950A CA2409950A CA2409950A1 CA 2409950 A1 CA2409950 A1 CA 2409950A1 CA 002409950 A CA002409950 A CA 002409950A CA 2409950 A CA2409950 A CA 2409950A CA 2409950 A1 CA2409950 A1 CA 2409950A1
Authority
CA
Canada
Prior art keywords
composition
hours
desglymidodrine
composition according
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002409950A
Other languages
English (en)
Inventor
Peder Mohr Olsen
Claus Sundgreen
Ann Christina Schultz
Jimmy Hirschsprung Schlyter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Austria GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/823,093 external-priority patent/US6761904B2/en
Priority claimed from PCT/DK2001/000214 external-priority patent/WO2001074335A1/fr
Application filed by Individual filed Critical Individual
Publication of CA2409950A1 publication Critical patent/CA2409950A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nouvelles compositions pharmaceutiques comprenant du desglymidodrine ou un sel pharmaceutiquement acceptable de celui-ci en tant que substance médicamenteuse active. Le desglymidodrine est un métabolite actif du promédicament midodrine. La composition pharmaceutique peut se présenter selon une posologie acceptable pour l'administration orale, parentérale, mucosale, nasale, sublinguale, buccale, topique, vaginale, rectale, oculaire, etc. Une composition pharmaceutique de l'invention peut avoir la forme d'une composition à libération immédiate et/ou modifiée ou être destinée à libérer la substance médicamenteuse active, le desglymidodrine, de façon relativement rapide afin de permettre à l'effet thérapeutique de se manifester assez rapidement. Les compositions ont une durée de conservation appropriée, c'est-à-dire que le desglymidodrine contenu dans la composition n'est pas sujet à une dégradation sensible lors du stockage dans des conditions normalement acceptables pour les produits pharmaceutiques. L'invention concerne aussi un procédé pour traiter des animaux tels que les mammifères et les humains avec une nouvelle composition pharmaceutique comprenant du desglymidodrine. Elle concerne aussi un nouveau procédé d'utilisation du desglymidodrine dans le traitement du choc septique et un procédé pour traiter des mammifères (tels que les humains) souffrant du choc septique avec une quantité suffisante de desglymidodrine.
CA002409950A 2000-05-26 2001-05-23 Compositions pharmaceutiques comprenant du desglymidodrine en tant que substance medicamenteuse active Abandoned CA2409950A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200000841 2000-05-26
DKPA200000841 2000-05-26
US09/823,093 2001-03-29
US09/823,093 US6761904B2 (en) 2000-03-31 2001-03-29 Pharmaceutical kit comprising midodrine as active drug substance
PCT/DK2001/000214 WO2001074335A1 (fr) 2000-03-31 2001-03-29 Composition pharmaceutique contenant de la midodrine comme substance medicamenteuse active
DKPCT/DK01/00214 2001-03-29
PCT/DK2001/000362 WO2001089473A1 (fr) 2000-05-26 2001-05-23 Compositions pharmaceutiques comprenant du desglymidodrine en tant que substance medicamenteuse active

Publications (1)

Publication Number Publication Date
CA2409950A1 true CA2409950A1 (fr) 2001-11-29

Family

ID=27222187

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002409950A Abandoned CA2409950A1 (fr) 2000-05-26 2001-05-23 Compositions pharmaceutiques comprenant du desglymidodrine en tant que substance medicamenteuse active

Country Status (4)

Country Link
EP (1) EP1289493A1 (fr)
AU (1) AU2001260089A1 (fr)
CA (1) CA2409950A1 (fr)
WO (1) WO2001089473A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1318674B1 (it) * 2000-08-08 2003-08-27 Nicox Sa Faramaci per l'incontinenza.
JP2003300873A (ja) * 2002-04-12 2003-10-21 Nitto Denko Corp 貼付剤およびその製造方法
US8157788B2 (en) * 2003-11-06 2012-04-17 Paolo L. Manfredi Multi-site drug delivery platform
CA2936748C (fr) 2014-10-31 2017-08-08 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
WO2019126770A1 (fr) * 2017-12-22 2019-06-27 Xenamed Corp. Compositions d'hydrochlorure de midodrine à libération prolongée et procédés d'utilisation
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
WO2021198995A1 (fr) * 2020-04-02 2021-10-07 Cadila Healthcare Limited Solutions parentérales aqueuses stables de desglymidodrine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610174A (en) * 1995-06-02 1997-03-11 Synaptic Pharmaceutical Corporation Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence
CN1422150A (zh) * 2000-03-31 2003-06-04 尼科米德奥地利有限公司 含有米多君和/或脱甘氨酸米多君的控释药物组合物

Also Published As

Publication number Publication date
AU2001260089A1 (en) 2001-12-03
EP1289493A1 (fr) 2003-03-12
WO2001089473A1 (fr) 2001-11-29

Similar Documents

Publication Publication Date Title
US20020147232A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance
EP0954337B1 (fr) Absorption intestinale de nicotine pour traiter les etats repondant a la nicotine
KR100341829B1 (ko) 방출특성이변형된다-유니트투여량조성물
JP4758064B2 (ja) 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬
EP1558220B1 (fr) Compositions orales pour le traitement du diabete
US6761904B2 (en) Pharmaceutical kit comprising midodrine as active drug substance
AU2002303897B2 (en) System for osmotic delivery of pharmaceutically active agents
EP2387994A1 (fr) Systèmes d'administration de médicaments comportant des médicaments faiblement basiques et acides organiques
US7070803B2 (en) Controlled release pharmaceutical composition for oral use containing midodrine and/or active metabolite, desglymidodrine
EP1631263B1 (fr) Comprime orodispersible multicouche
PL195780B1 (pl) Kuleczka o kontrolowanym uwalnianiu, sposób wytwarzania kuleczki, zawierająca je kapsułka i tabletka oraz zastosowanie kuleczek
CZ245198A3 (cs) Použití nikotinu, komplex nikotinu a polyakrylátu a způsob jeho přípravy a farmaceutické kompozice
JP2013249305A (ja) 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系
LT3664B (en) Sustained release drug formation containing a tramadol salt
JP2003513918A (ja) トルテロジン含有医薬組成物及びその使用
JP2003300907A (ja) 抗真菌製剤、及びその製造方法ならびに使用
EP1267841B1 (fr) Composition pharmaceutique a liberation controlee a base de midodrine et/ou desglymidodrine
CA2409950A1 (fr) Compositions pharmaceutiques comprenant du desglymidodrine en tant que substance medicamenteuse active
HRP20031057A2 (en) Tablet comprising cetirizine and pseudoephedrine
Datir Recent advances in mucoadhesive buccal drug delivery system and its marketed scope and opportunities
PL191868B1 (pl) Zastosowanie lewosimendanu do wytwarzania preparatu do podawania przez błonę śluzową
EP1465607B1 (fr) Compositions pharmaceutiques a liberation modifiee
JP4945043B2 (ja) モルシドミンの放出時間延長を伴う経口投与用新規生薬製剤
CA2403958A1 (fr) Composition pharmaceutique contenant de la midodrine comme substance medicamenteuse active
JP2023523738A (ja) 視床下部性肥満症の処置

Legal Events

Date Code Title Description
FZDE Dead